|Articles|October 14, 2020
- Pharmaceutical Executive-10-01-2020
- Volume 40
- Issue 10
Pharmaceutical Executive, October 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
The SPAC Makes a Comeback!almost 5 years ago
Leadership and Industry Imagealmost 5 years ago
Assets in Anxious Times: Patient Hubs Demonstrate Value During COVID-19almost 5 years ago
The Interplay Between COVID-19 Pandemic and NCD Epidemicalmost 5 years ago
FDA Struggles to Retain Credibilityalmost 5 years ago
Critical Connection: Patient Services and Product Launchalmost 5 years ago
Mastering the Transition From Academia to Industryalmost 5 years ago
Smoothing Access Pathalmost 5 years ago
The COVID Boost to AI in Global Healthalmost 5 years ago
Speed and SensitivityNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
2
AstraZeneca to Announce Deal with Trump Administration: Report
3
Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina
4
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
5
